Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers propose using a less-than-one-in-a-million level—or the absence of minimal residual disease—to measure drugs’ effectiveness.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
Yolanda Brunson-Sarrabo was diagnosed with smoldering myeloma in 2008.
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease.
Mouse study shows how transplanting patients’ own healthy blood stem cells can curb cancer, opening door to better treatments.
In 2009, March was declared Myeloma Awareness Month (MAM).
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
ClonoSEQ assay tests for minimal residual disease, or very low levels of cancer cells in bone marrow.
Less than 5 percent of Black patients were involved in trials for 24 out of 31 cancer drugs approved since 2015.
The findings lay the groundwork for tests that can identify whether the disease is likely to progress rapidly.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.